(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 January 2015 (15.01.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/004239 A1

(51) International Patent Classification:
C12P 21/00 (2006.01) *C12N 9/10* (2006.01)

(21) International Application Number:
PCT/EP2014/064818

(22) International Filing Date:
10 July 2014 (10.07.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13175997.9 10 July 2013 (10.07.2013) EP

(71) Applicants: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **GLYKOS FINLAND OY** [FI/FI]; Viikinkaari 6, FI-00790 Helsinki (FI).

(72) Inventors: **NATUNEN, Jari**; Oolannintie 10 E 18, FI-01520 Vantaa (FI). **LANDOWSKI, Christopher**; Lohkopellontie 3 A 15, FI-00650 Helsinki (FI). **SALOHEIMO, Markku**; Kyntäjäntie 18 b, FI-00390 Helsinki (FI). **OSTERMEIER, Christian**; Novartis Pharma AG, Werk Klybeck Postfach, CH-4002 Basel (CH). **SOMMER, Benjamin Patrick**; Novartis Pharma AG, Werk Klybeck Postfach, CH-4002 Basel (CH). **WAHL, Ramon**; Novartis Pharma AG, Werk Klybeck Postfach, CH-4002 Basel (CH).

(74) Agent: **CABINET PLASSERAUD**; 235 cours Lafayette, F-69006 Lyon (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2015/004239 A1

(54) Title: PRODUCTION OF GLYCOPROTEINS HAVING INCREASED N-GLYCOSYLATION SITE OCCUPANCY

(57) Abstract: The present disclosure relates to compositions and methods useful for the production of heterologous proteins with increased N-glycosylation site occupancy in filamentous fungal cells, such as Trichoderma cells. More specifically, the invention provides a filamentous fungal cell comprising i. one or more mutation that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation(s), ii. a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase, and iii. a polynucleotide encoding a heterologous glycoprotein, wherein said catalytic subunit of oligosaccharyl transferase is selected from Leishmania oligosaccharyl transferase catalytic subunits.